Coronavirus and COVID-19


SARS-CoV-2 Test Systems

Rapid antigen tests for the detection of the SARS-CoV-2 coronavirus, which are subject to reimbursement claims according to section 1 paragraph 1 of the Coronavirus Testing Ordinance (Coronavirus-Testverordnung, TestV)

With the amendment of the Coronavirus Testing Ordinance (TestV) on 29 June 2022, there are new regulations regarding the reimbursement of rapid antigen tests. The claim pursuant to section 1 (1) sentence 1 with regard to diagnostics by means of POC antigen tests (point-of-care antigen tests) is limited to antigen tests which have been included in the common list of Coronavirus rapid antigen tests adopted by the Health Security Committee of the European Union (HSC Common RAT List).

This list, which also contains information on the criteria for inclusion in the list, is now available on the European Union's website at:

European Commisson: Public Health - Common list of Corona antigen rapid tests

The market overview in the BfArM list in accordance with section 1 paragraph 1 sentence 6 of the TestV (old version) as well as the list with the comparative evaluation of the sensitivity of SARS-CoV-2 rapid antigen tests are thus discontinued.




  1. Role of the Paul-Ehrlich-Institut
  2. COVID-19 Vaccines
  3. Proof of vaccination within the meaning of the Infection Protection Act (IfSG)
  4. FAQ Coronavirus
  5. Biomedicines
  6. Safety of COVID-19 Vaccines
  7. Research Work
  8. SARS-CoV-2 Test Systems